FLGTFulgent Genetics, Inc.
Services-Medical Laboratories
- Revenue
- $323M
- 14% YoY
- Operating margin
- -28.2%
- 8.3% YoY
- EBITDA
- −$67M
- 37% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired12% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-11% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear5% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $993M | $619M | $289M | $283M | $323M | 14% |
| Operating income | $676M | $179M | −$196M | −$74M | −$91M | 23% |
| Net income | $507M | $143M | −$168M | −$43M | −$61M | 42% |
| Operating cash flow | $539M | $254M | $27M | $21M | −$102M | 583% |
| Capex | $24M | $19M | $22M | $40M | $23M | 44% |
| Stock-based comp | $16M | $33M | $43M | $44M | $40M | 11% |
| Buybacks | — | $74M | $25M | $225K | $11M | 4737% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.